| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Pyrene-1,3,6,8-tetrasulfonic acid tetrasodium does not target a specific protein or enzyme. Its utility as a fluorescent probe is based on its photophysical properties, particularly its ability to form excimers, which is sensitive to the local environment and molecular proximity.
|
|---|---|
| ln Vitro |
The in vitro activity of this compound is characterized by its strong fluorescence and excimer formation properties. Pyrene derivatives exhibit monomer fluorescence in the UV-blue region and excimer fluorescence at longer wavelengths when two pyrene molecules are in close proximity. This property is used to study molecular interactions, membrane dynamics, and protein conformational changes.
|
| ln Vivo |
Pyrene-1,3,6,8-tetrasulfonic acid tetrasodium is not used as a therapeutic agent. Its in vivo utility is limited to research applications as a fluorescent probe for studying molecular interactions and dynamics. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro assays for this compound involve measuring its fluorescence properties, including monomer and excimer emission, under various conditions. The ratio of excimer to monomer fluorescence provides information about the local concentration and proximity of pyrene molecules, enabling studies of molecular interactions and dynamics.
|
| Cell Assay |
For in vitro cellular experiments, this compound can be used as a fluorescent probe to study membrane dynamics, protein interactions, and other biological processes. Cells are incubated with the dye and analyzed by fluorescence microscopy or spectroscopy.
|
| Animal Protocol |
In vivo animal experiments with this compound are not typically performed, as the compound is primarily used as a fluorescent probe for in vitro studies. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of this compound have not been characterized, as it is a research-use fluorescent probe rather than a drug candidate. The compound has a molecular weight of 610.42 g/mol and is water-soluble. It should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for this compound has not been systematically evaluated, as it is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| References |
|
| Additional Infomation |
Pyrene-1,3,6,8-tetrasulfonic acid tetrasodium is a water-soluble fluorescent dye used for studying molecular interactions, membrane dynamics, and protein conformational changes through pyrene excimer formation. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C16H6NA4O12S4
|
|---|---|
| Molecular Weight |
610.43
|
| Exact Mass |
609.833
|
| CAS # |
59572-10-0
|
| Related CAS # |
6528-53-6 (Parent)
|
| PubChem CID |
101082
|
| Appearance |
Light yellow to yellow solid powder
|
| Melting Point |
102-104 °C(lit.)
|
| LogP |
4.523
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
36
|
| Complexity |
942
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C3C(=C(C=C2S(=O)(=O)[O-])S(=O)(=O)[O-])C=CC4=C(C=C(C1=C43)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+]
|
| InChi Key |
UZBIRLJMURQVMX-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C16H10O12S4.4Na/c17-29(18,19)11-5-13(31(23,24)25)9-3-4-10-14(32(26,27)28)6-12(30(20,21)22)8-2-1-7(11)15(9)16(8)10;;;;/h1-6H,(H,17,18,19)(H,20,21,22)(H,23,24,25)(H,26,27,28);;;;/q;4*+1/p-4
|
| Chemical Name |
tetrasodium;pyrene-1,3,6,8-tetrasulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6382 mL | 8.1909 mL | 16.3819 mL | |
| 5 mM | 0.3276 mL | 1.6382 mL | 3.2764 mL | |
| 10 mM | 0.1638 mL | 0.8191 mL | 1.6382 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
